Faculty, Staff and Student Publications
Publication Date
12-1-2022
Journal
Cancer Prevention Research
DOI
10.1158/1940-6207.CAPR-22-0106
PMID
35981902
PMCID
PMC9762336
PubMedCentral® Posted Date
August 2022
PubMedCentral® Full Text Version
Post-print
Abstract
Our results show that everolimus delays mammary tumor formation in multiple mouse models, suggesting that mTOR inhibitors will be useful for the prevention of ER-negative and triple-negative breast cancer in humans. See related Spotlight, p. 787.
Keywords
Humans, Mice, Animals, Female, Receptors, Estrogen, TOR Serine-Threonine Kinases, Mammary Neoplasms, Animal, Everolimus, Breast Neoplasms
Published Open-Access
yes
Recommended Citation
Mazumdar, Abhijit; Tahaney, William M; Hill, Jamal L; et al., "Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer" (2022). Faculty, Staff and Student Publications. 343.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/343
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Obstetrics and Gynecology Commons, Oncology Commons, Women's Health Commons